5,748 Medtronic PLC $MDT Shares Acquired by Vest Financial LLC

Vest Financial LLC boosted its stake in Medtronic PLC (NYSE:MDT) by 0.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 639,468 shares of the medical technology company’s stock after buying an additional 5,748 shares during the period. Vest Financial LLC’s holdings in Medtronic were worth $55,180,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MDT. Cantor Fitzgerald Investment Advisors L.P. boosted its stake in Medtronic by 2.0% during the third quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 167,041 shares of the medical technology company’s stock valued at $14,414,000 after buying an additional 3,243 shares in the last quarter. White Lighthouse Investment Management Inc. grew its holdings in Medtronic by 25.9% during the third quarter. White Lighthouse Investment Management Inc. now owns 3,390 shares of the medical technology company’s stock worth $293,000 after acquiring an additional 698 shares during the period. AMG Asset Management Group Inc. lifted its holdings in Medtronic by 5.7% in the 3rd quarter. AMG Asset Management Group Inc. now owns 2,869 shares of the medical technology company’s stock valued at $248,000 after acquiring an additional 154 shares during the last quarter. Trifecta Capital Advisors LLC acquired a new stake in Medtronic in the 3rd quarter valued at about $84,000. Finally, Albion Financial Group UT grew its stake in shares of Medtronic by 8.0% in the 3rd quarter. Albion Financial Group UT now owns 68,300 shares of the medical technology company’s stock worth $5,894,000 after purchasing an additional 5,064 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

MDT opened at $93.05 on Thursday. The stock has a fifty day moving average of $91.23 and a 200-day moving average of $85.16. The firm has a market capitalization of $119.02 billion, a P/E ratio of 22.92, a PEG ratio of 2.21 and a beta of 0.55. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. Medtronic’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts forecast that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Insider Activity at Medtronic

In other Medtronic news, CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the sale, the chief executive officer owned 277,866 shares in the company, valued at $26,397,270. This represents a 15.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president directly owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 61,903 shares of company stock valued at $5,889,203. Corporate insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Wells Fargo & Company increased their target price on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research note on Wednesday, September 2nd. Weiss Ratings upgraded Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday. TD Cowen reissued a “buy” rating and set a $110.00 price objective on shares of Medtronic in a research note on Wednesday, September 30th. Needham & Company LLC restated a “buy” rating on shares of Medtronic in a report on Thursday, September 17th. Finally, Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Eighteen equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $102.88.

Medtronic Company Profile

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.